How big is OraSure Technologies, Inc.?

As of Jun 18, OraSure Technologies, Inc. has a market capitalization of 210.19 million, with net sales of 161.63 million and a net profit of -31.95 million over the latest four quarters. The company reported shareholder's funds of 410.34 million and total assets of 479.66 million as of Dec 24.

Market Cap: As of Jun 18, OraSure Technologies, Inc. has a market capitalization of 210.19 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, OraSure Technologies, Inc. reported net sales of 161.63 million and a net profit of -31.95 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 410.34 million and total assets of 479.66 million.

What does OraSure Technologies, Inc. do?

OraSure Technologies, Inc. develops and sells oral fluid diagnostic products and specimen collection devices, with a market cap of approximately $210.19 million. As of March 2025, the company reported net sales of $30 million but incurred a net loss of $16 million.

Overview: <BR>OraSure Technologies, Inc. is involved in the development, manufacture, marketing, and sale of oral fluid diagnostic products and specimen collection devices in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 30 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 210.19 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.62 <BR>Return on Equity: -6.96% <BR>Price to Book: 0.53<BR><BR>Contact Details: <BR>Address: 150 WEBSTER ST, BETHLEHEM PA: 18015 <BR>Tel: 1 503 6416115 <BR>Fax: 1 610 8821830 <BR>Website: http://www.orasure.com

Should I buy, sell or hold OraSure Technologies, Inc.?

Who are in the management team of OraSure Technologies, Inc.?

As of March 2022, the management team of OraSure Technologies, Inc. includes Dr. Stephen Tang (CEO), Mr. Michael Celano (Chairman), and several independent directors, ensuring a diverse leadership structure.

As of March 2022, the management team of OraSure Technologies, Inc. includes the following individuals:<BR><BR>- Mr. Michael Celano, Independent Chairman of the Board<BR>- Dr. Stephen Tang, President, Chief Executive Officer, and Director<BR>- Lelio Marmora, Director<BR>- Ms. Mara Aspinall, Independent Director<BR>- Mr. James Datin, Independent Director<BR>- Mr. Eamonn Hobbs, Independent Director<BR>- Mr. Ronny Lancaster, Independent Director<BR><BR>In summary, the management team features a mix of independent directors and key executives, highlighting a diverse leadership structure.

Is OraSure Technologies, Inc. overvalued or undervalued?

As of February 25, 2025, OraSure Technologies, Inc. is considered overvalued and risky due to negative financial ratios, including a Price to Book Value of 0.55 and a negative ROE of -6.96%, indicating it is priced higher than its underlying value compared to peers.

As of 25 February 2025, the valuation grade for OraSure Technologies, Inc. has moved from expensive to risky, indicating a shift in perception regarding its market standing. Based on the available metrics, the company appears to be overvalued, particularly given its negative financial ratios. The Price to Book Value stands at 0.55, while the EV to EBITDA is 1.09, both suggesting that the market may be pricing the stock higher than its underlying value. Additionally, the negative ROE of -6.96% further underscores the company's struggles in generating returns for shareholders.<BR><BR>In comparison to its peers, OraSure's valuation ratios highlight its precarious position; for instance, Silk Road Medical, Inc. has a significantly higher EV to EBITDA of 18.1243, while Castle Biosciences, Inc. shows a much worse P/E ratio of -71.3566. These comparisons illustrate that OraSure is not only struggling but is also priced higher than some of its less favorable competitors. Although recent stock performance data against the S&P 500 is not available, the overall financial indicators suggest that OraSure Technologies, Inc. is currently overvalued in the market.

Is OraSure Technologies, Inc. technically bullish or bearish?

As of September 11, 2025, OraSure Technologies, Inc. shows a neutral trend with mixed signals: mildly bullish MACD and OBV on weekly and monthly time frames, but bearish moving averages and conflicting Bollinger Bands.

As of 11 September 2025, the technical trend for OraSure Technologies, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish trend on both weekly and monthly time frames, while the Bollinger Bands indicate a mildly bullish weekly trend but a bearish monthly trend. The KST is bullish weekly but bearish monthly, and the moving averages are mildly bearish on a daily basis. The OBV is mildly bullish on both weekly and monthly time frames. There are no multi-period return figures available for comparison with the S&P 500.